Printer Friendly

T-CELL SCIENCES' FIRST CELLFREE DIAGNOSTIC PRODUCT APPROVED FOR USE IN JAPAN

 T-CELL SCIENCES' FIRST CELLFREE DIAGNOSTIC PRODUCT APPROVED
 FOR USE IN JAPAN
 CAMBRIDGE, Mass., June 2 /PRNewswire/ -- T Cell Sciences, Inc. (NASDAQ: TCEL), announced today that its Japanese partner, Yamanouchi Pharmaceutical Co. Ltd., has received approval from Japanese regulatory authorities to market the CELLFREE(R) IL-2R Bead Assay Kit for monitoring disease activity in adult T cell leukemia (ATL) patients. This kit will be marketed in Japan exclusively by Yamanouchi under an agreement with T Cell Diagnostics, a subsidiary of T Cell Sciences, and product will be supplied by T Cell Diagnostics. Yamanouchi anticipates launching the CELLFREE IL-2R Bead Assay Kit in the third quarter of 1992.
 "This approval marks the entry of our first CELLFREE product in the Japanese market and represents acceptance of a new way of monitoring disease activity in patients," said William Gelb, Ph.D., chairman and chief executive officer of T Cell Diagnostics. "Yamanouchi will expand the market opportunity for the CELLFREE product line by establishing additional uses for the IL-2R kit and commercializing other CELLFREE products."
 T Cell Diagnostics has received FDA approval to market the CELLFREE IL-2R Bead Assay Kit in the U.S. as an aid for monitoring the response to therapy in patients with hairy cell leukemia. The company has filed a supplemental application with the FDA to market the kit for monitoring renal transplant rejection and is actively engaged in other pre-clinical and clinical trials to demonstrate the usefulness of this test in other transplant situations and in autoimmune diseases. The kit is marketed currently in Europe for research use. The technology used in the CELLFREE product line is patented in the U.S. and patents are pending in other parts of the world.
 CELLFREE products measure cell surface proteins which have been shed into the bloodstream. In several disease situations, including ATL, it has been shown that levels of shed IL-2 receptors in the serum correspond with disease activity. In Japan, there are an estimated 1,000 patients with ATL. In addition, there are approximately 1.2 million carriers of the human T cell leukemia virus (HTLV) which causes AT land a substantial number of these carriers may develop ATL in the future.
 Yamanouchi Pharmaceutical Co. Ltd. is a Japan-based multinational health care company. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures and markets highly innovative diagnostic and research products around the world. Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer.
 -0- 6/2/92
 /CONTACT: William Gelb, Ph.D., chairman and chief executive officer, or Susan Primrose, manager-corporate development & communications, of T Cell Diagnostics, 617-621-1400/
 (TCEL) CO: T Cell Sciences, Inc.; Yamanouchi Pharmaceutical Co. Ltd. ST: Massachusetts IN: MTC SU:


SH -- NE007 -- 6188 06/02/92 11:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1992
Words:477
Previous Article:ROYAL CRESCENT VALLEY FILES COMPLAINT IN THE UNITED STATES DISTRICT COURT
Next Article:NEW MONITOR FUND PURSUES INCOME THROUGH PORTFOLIO OF MORTGAGE-BACKED SECURITIES
Topics:


Related Articles
T CELL SCIENCES ANNOUNCES UPDATE ON TRAx(R) CD4 SUBMISSION
T CELL SCIENCES' SUBSIDIARY RECEIVES FDA CLEARANCE TO MARKET TRAx CD4
T CELL SCIENCES REPORTS RESTRUCTURING IMPROVEMENTS IN FIRST QUARTER 1996
T CELL SCIENCES, INC. RECEIVES U.S. PATENT FOR TRAX PRODUCTS
Matritech Reaches Marketing Agreement with Spanish Distributor
T Cell Sciences Receives U.S. Patent Allowance For TRAx
Matritech Announces Approval in Japan of the NMP22(R) Test Kit for Both Monitoring and Screening of Bladder Cancer Patients
Matritech and Laboratory Corporation of America(R) Holdings to Offer Matritech's NMP22(R) Bladder Cancer Test
Johns Hopkins Medical Institutions Uses Matritech's NMP22(R) Bladder Cancer Test.
Clinical Utility of Matritech's NMP22 Test for Early Detection of Bladder Cancer Demonstrated by Cleveland Clinic Researchers.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters